Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NBPF member 25, pseudogene (NBPF25P) is a member of the neuroblastoma breakpoint family (NBPF), a large gene family characterized by multiple segmental duplications in the human genome, mostly on chromosome 1[1][2][3][4]. NBPF25P is classified as a pseudogene, meaning it does not encode a functional protein due to frameshift or nonsense mutations in its coding sequence[1][2]. Pseudogenes like NBPF25P may be transcribed but typically lack protein-coding capacity. There is currently no evidence that NBPF25P functions as a receptor, enzyme, transporter, or direct therapeutic target[1][3][4]. Its closest functional relatives in the NBPF family have been studied in the context of neuroblastoma and other diseases—including roles in brain development, cognitive disability, autism, and schizophrenia, largely via gene dosage effects of protein-coding family members and associated copy number variants[2][4]. However, these disease links do not apply directly to NBPF25P as it is non-functional as a protein and not a direct drug target. Notes: - NBPF25P is not a therapeutic target and is instead annotated as a non-functional genomic locus (pseudogene), explaining why all fields regarding function, mechanism, and drugs are null[1][3][4]. - This entity is sometimes included in gene panels or genomic and transcriptomic studies due to proximity to relevant functional NBPF genes but should not be confused with active protein-coding genes[2][4]. - As a pseudogene, it does not belong to conventional classes such as "receptor", "transporter", or "enzyme" and has no validated function or druggability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NBPF member 25, pseudogene (NBPF25P).